Bulbar function in children with spinal muscular atrophy type 1 treated with nusinersen

Le résumé fourni par la source

AIM: To describe bulbar function trajectories in patients with spinal muscular atrophy (SMA) type 1 treated with nusinersen in the UK and Italy. METHOD: In two previously reported, retrospective, observational cohort studies, we observed the 2-year change in the Children's Eating and Drinking Ability Scale (CEDAS) (the revised and optimized version of the Paediatric Functional Oral Intake Scale [p-FOIS]) and Oral and Swallowing Ability Tool (OrSAT) in 44 patients treated on average at 8.3 months (interquartile range = 4.1-14.4 months), with data collected every 6 months from treatment initiation. [Correction added on 30 June 2025 after first online publication: In the preceding sentence, 11.2 months (interquartile range = 4.1-24.7 months) has been changed to 8.3 months (interquartile range = 4.1-14.4 months).] RESULTS: The Italian cohort had more participants in the 1b group (symptom onset >2 weeks and <3 months), while the UK had more participants in the 1c group (symptom onset <6 months). Over 2 years, the p-FOIS/CEDAS captured lack of bulbar improvement in the 1b group, with 40% displaying stability and 45% showing decline; in the 1c group, stability was captured (71%). OrSAT captured improvement in 47% of the 1b group and 43% of the 1c group at 2 years; this was predominantly because of age-related speech acquisition and feeding viscosities, where the item was not age-appropriate at baseline. INTERPRETATION: The p-FOIS/CEDAS and OrSAT measures capture complementary information on the effect of disease-modifying treatments (DMTs) on bulbar function. Further studies are required to understand bulbar function trajectories in symptomatic and presymptomatic cohorts with SMA receiving different DMTs.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.